![]() |
市場調查報告書
商品編碼
2133425
可拆卸線圈市場規模、佔有率和趨勢分析 |全球| 2026–2032 | 包括裸鉑金可拆卸線圈市場和塗層可拆卸線圈市場Detachable Coil Market Size, Share & Trends Analysis | Global | 2026-2032 | Includes: Bare Platinum Detachable Coil Market and Coated Detachable Coil Market |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2025年全球可拆卸線圈市場價值約4.14億美元。預計該市場將以約0.2%的複合年成長率成長,到2032年達到約4.18億美元。
本報告重點在於用於顱內動脈瘤血管內治療的無塗層鉑金可移除彈簧圈和塗層可移除彈簧圈。該報告對銷售量、手術量、平均售價、市場規模、成長率和企業市場占有率進行了定量分析,包括截至2022年的歷史數據和截至2032年的預測數據。
市場成長的主要阻礙因素是其他血管內治療技術的日益普及。隨著血流導向裝置和骶管內裝置獲得臨床認可,其適應症不斷擴大,動脈瘤治療中對彈簧圈的依賴性正在降低,從而限制了該領域手術數量的成長。
另一方面,診斷成像技術的進步和線圈設計的不斷改進正在推動要素,從而抵消了上述影響。未破裂動脈瘤檢測準確性的提高擴大了可治療的患者範圍,而線圈形狀、柔軟性和輸送性能的改進則確保了線圈療法仍然是各種位置和形態動脈瘤的首選治療方法。
市場概覽
可移除彈簧圈是治療顱內動脈瘤閉塞的成熟療法,長期臨床證據表明,與開放式神經外科夾閉術相比,其安全性和有效性均優於傳統方法。在更廣泛的神經血管介入領域,可移除彈簧圈市場已趨於成熟,其成長近乎停滯,這不僅反映了彈簧圈技術的臨床持久性,也反映了來自新型血管內治療的競爭壓力——這些新型血管內治療正在逐步取代彈簧圈,佔據其適用範圍。
血流導引裝置和囊內裝置的日益普及是可移除彈簧圈市場面臨的最重大結構性挑戰。血流導向裝置可將血液從動脈瘤分流,促進囊內血栓形成,主要用於治療大型或巨大型寬頸動脈瘤。囊內裝置可支撐動脈瘤頸部,在主要市場獲得監管部門批准後,其應用日益廣泛,近期已有多個產品獲批或正在上市過程中。隨著這些技術適應症的擴大和外科醫生技術的不斷提高,在以往兩種方法均有效的病例中,它們正逐漸取代彈簧圈。
影像技術的進步在一定程度上抵消了需求趨勢。 CT血管造影術、腦血管造影術和MRI等技術能夠檢測出以往被忽視或未確診的動脈瘤,擴大了適合血管內治療的患者族群。這一趨勢也推動了治療方向向較小動脈瘤的轉變,而微纖維彈簧圈系統非常適合治療這些體積較小的動脈瘤,因此市場對微纖維彈簧圈系統的需求正在逐漸成長。
線圈結構和設計的進步持續改善了臨床療效,醫生在合適的病例中仍然傾向於線圈治療。傳統的螺旋形線圈主要在單一平面展開,而現在則採用可在多個方向展開的複雜線圈形狀,從而提高了動脈瘤囊閉塞的品質和完整性。包括國際蛛網膜下腔動脈瘤試驗數據在內的關鍵臨床證據支持血管內線圈栓塞術在治療破裂性顱內動脈瘤方面優於神經外科夾閉術,從而維持了在適當適應症中使用線圈的臨床合理性。
醫學影像技術的進步
影像技術的進步提高了未破裂顱內動脈瘤的檢出率。腦血管血管造影術、CT 和 MRI 均可識別未破裂動脈瘤,隨著全球影像品質和普及程度的不斷提高,越來越多的患者符合血管內治療的條件。確診患者數量的增加將推動可移除彈簧圈銷售量在預測期內逐步增加。早期檢測準確性的提高也推動了臨床治療小型動脈瘤的趨勢,而微纖維彈簧圈系統非常適合此類病例,從而促進了對該產品的需求。國際蛛網膜下腔動脈瘤試驗 (ISAT) 進行的 ISAT 研究表明,與神經外科手術相比,血管內彈簧圈栓塞術顯著提高了蛛網膜下腔出血一年後的無併發症存活率。這進一步強化了醫師在解剖結構適當的病例中優先選擇彈簧圈栓塞術的趨勢。
線圈結構與設計的改進
自可移除彈簧圈技術誕生以來,其結構和設計已顯著改進。幾何形狀、柔軟性和輸送方式的進步,使得彈簧圈更加耐用,能夠在複雜的解剖結構內靈活穿行,並更徹底、更穩定地填充動脈瘤囊。市場趨勢是採用更靈活、更短的彈簧圈,以便更精準地放置,並降低彈簧圈移位的風險。可向多個方向展開的複雜形狀彈簧圈,拓寬了彈簧圈栓塞術可有效治療的動脈瘤形態範圍。外科醫生現在可以先用彈簧圈包圍動脈瘤,然後用額外的彈簧圈填充瘤囊,從而實現完全閉塞。這些設計上的進步使得彈簧圈栓塞術仍然是治療多種類型動脈瘤的首選方法,即使其他技術的應用日益廣泛,彈簧圈的需求仍然強勁。
引入競爭性技術
血流導引裝置能夠改變血液流向,使其遠離動脈瘤,並促進動脈瘤內血栓形成,目前正從可移除彈簧圈手中奪取大量市場佔有率。這些裝置主要用於治療頸部較寬的大型或巨大型腦動脈瘤,但隨著醫生經驗的積累,其臨床應用範圍正在擴大。支撐動脈瘤頸部的囊內裝置也備受關注。 MicroVention公司的WEB裝置早在10年前就獲得了CE認證,在獲得FDA上市前批准後,其應用率已相當高。同時,美敦力公司和Cerus Endovascular公司也推出了各自的競爭產品,進軍該領域。隨著對這些技術的臨床理解不斷加深,以及核准適應症的擴大,在以往兩種方法均被認為有效的病例中,血流導向裝置正逐漸取代可移除彈簧圈,從而對彈簧圈治療的成長和市場價值構成持續的競爭壓力。
關於線圈療法適應症的形態學限制
並非所有顱內動脈瘤都適合彈簧圈栓塞治療,這自然限制了可移除彈簧圈手術的總例數。動脈瘤的位置、形態和解剖特徵會影響血管內卷取或手術夾閉的選擇。由於手術入路較為容易,大腦中動脈瘤較常採用夾閉術,而大腦後動脈瘤幾乎總是採用彈簧圈栓塞治療。一般來說,對於瘤頸較寬或瘤體與瘤頸比小於1.5的動脈瘤,夾閉術是首選。另一方面,當動脈瘤壁鈣化且手術治療困難時,則首選彈簧圈栓塞。這些形態學因素對可採用彈簧圈栓塞治療的動脈瘤病例比例設定了結構性上限,預計在預測期內此限制不會發生顯著變化。
The global detachable coil market was valued at approximately $414 million in 2025. The market is expected to grow at a compound annual growth rate (CAGR) of approximately 0.2%, reaching approximately $418 million by 2032.
This report covers bare platinum detachable coils and coated detachable coils used in the endovascular treatment of intracranial aneurysms. The report quantifies unit sales, procedure numbers, average selling prices (ASPs), market values, growth rates, and company shares, with historical data back to 2022 and forecasts through 2032.
The primary constraint on market growth is the increasing adoption of alternative endovascular technologies. Flow diverters and intrasaccular devices are gaining clinical acceptance and expanding their approved indications, reducing reliance on coils in aneurysm treatment and limiting procedural volume growth in this segment.
Improved imaging technologies and continued advances in coil design provide an offsetting demand driver. Better detection of unruptured aneurysms is expanding the treated patient population, while improvements in coil geometry, softness, and deliverability are maintaining coiling as the preferred treatment approach across a broad range of aneurysm locations and morphologies.
Market Overview
Detachable coils are an established treatment for intracranial aneurysm occlusion, supported by a long-term clinical evidence base that demonstrates their safety and efficacy relative to open neurosurgical clipping. The market occupies a mature position within the broader neurovascular intervention segment, with near-flat growth reflecting both the clinical durability of coil technology and the competitive pressure from newer endovascular alternatives that are gradually displacing coils from a growing share of eligible aneurysm cases.
The growing adoption of flow diverters and intrasaccular devices represents the most significant structural challenge to the detachable coil market. Flow diverters redirect blood away from the aneurysm, promoting clot formation within the sac, and are primarily used for large or giant wide-necked aneurysms. Intrasaccular devices that scaffold the aneurysm neck are gaining traction following regulatory approvals in major markets, with several products either recently approved or in the process of gaining market access. As these technologies expand their indications and surgeon familiarity grows, they continue to displace coils from procedures where either approach was previously viable.
Improved imaging technologies are providing a partially offsetting demand dynamic. CT angiography, cerebral angiography, and MRI are detecting aneurysms that would previously have remained undiagnosed, expanding the pool of patients who are candidates for endovascular treatment. This trend is also driving a shift toward treating smaller aneurysms, where microfiber coil systems are well suited to the smaller aneurysm volumes involved and contribute incremental unit demand to the market.
Advances in coil construction and design continue to improve clinical outcomes and sustain physician preference for coiling in appropriate cases. Complex shaped coils that deploy in multiple directions have replaced earlier helical designs that expanded primarily in one plane, improving the quality and completeness of aneurysm sac occlusion. Major clinical evidence, including data from the International Subarachnoid Aneurysm Trial, has reinforced the long-term efficacy of endovascular coiling compared to neurosurgical clipping for ruptured intracranial aneurysms, maintaining the clinical rationale for coil use across appropriate indications.
Market Drivers
Improved Imaging Technologies
Advances in imaging have allowed for increased detection of unruptured intracranial aneurysms. Cerebral angiography, CT, and MRI can all identify unruptured aneurysms, and as imaging quality and availability continue to improve globally, more patients are being identified as candidates for endovascular treatment. This growth in the diagnosed patient population supports incremental unit volume for detachable coils over the forecast period. Improved early detection is also driving a clinical trend toward the treatment of smaller aneurysms, where microfiber coil systems are well suited and add incremental unit demand. The ISAT study, conducted by the International Subarachnoid Aneurysm Trial Collaborative Group, demonstrated that endovascular coil treatment is significantly more likely to result in survival free of disability at one year following subarachnoid hemorrhage compared to neurosurgical treatment, reinforcing physician preference for coiling in anatomically appropriate cases.
Improved Coil Construction and Design
The construction and design of detachable coils have improved considerably since the segment was established. Advancements in geometry, softness, and deliverability have produced more durable coils capable of navigating complex anatomy and filling aneurysm sacs more thoroughly and consistently. The market has trended toward softer, shorter coil formats that provide more precise placement and reduce the risk of coil migration. Complex shaped coils that deploy in multiple directions have broadened the range of aneurysm morphologies that can be effectively treated by coiling, allowing surgeons to frame the aneurysm before filling the sac with additional coils for complete occlusion. These design advances maintain coiling as the preferred approach across a wide range of aneurysm types and sustain demand for coil units even as alternative technologies grow in adoption.
Market Limiters
Introduction of Competing Technologies
Flow diverter devices that redirect blood away from the aneurysm, promoting clot formation within the sac, are cannibalizing significant market share from detachable coils. These devices are primarily used to treat large or giant, wide-necked brain aneurysms, but clinical indications are expanding as physician experience accumulates. Intrasaccular devices that scaffold the aneurysm neck are also gaining traction. MicroVention's WEB device, which received CE marking a decade ago, is already seeing high adoption rates following FDA premarket approval, while Medtronic and Cerus Endovascular are working to enter this segment with their own competing products. As these technologies grow in clinical familiarity and expand approved indications, they continue to displace detachable coils in cases where either approach was previously considered viable, creating sustained competitive pressure on coil procedure volumes and market value growth.
Morphological Constraints on Coiling Eligibility
Not all intracranial aneurysms are amenable to treatment by coiling, which defines a natural boundary on the total addressable procedure volume for detachable coils. Aneurysm location, morphology, and anatomical characteristics influence the treatment decision between endovascular coiling and surgical clipping. Middle cerebral artery aneurysms are more frequently clipped due to easier surgical access in that region, while posterior artery aneurysms are coiled the majority of the time. Clipping is generally preferred for aneurysms with a wide neck or a dome-to-neck ratio below 1.5. Coiling is preferred when the aneurysm has calcified walls, which are difficult to treat surgically. These morphological considerations define a structural ceiling on the share of aneurysm cases that can be directed toward coil-based treatment, and this constraint is not expected to change meaningfully over the forecast period.
Market Coverage and Data Scope
Markets Covered and Segmentation
Competitive Analysis
Stryker was the leader in the global detachable coil market in 2025, with a primary focus on the bare platinum segment. The company's GDC 360 detachable coil is widely regarded as the gold standard for neurovascular aneurysm occlusion and played a foundational role in establishing endovascular coiling as a primary treatment modality for intracranial aneurysms. Stryker's deep heritage in this segment, combined with the clinical evidence base built around the GDC platform, supports its continued leadership position across major global markets.
Medtronic held the second-leading position in the detachable coil market in 2025. The company's AXIUM detachable coil system is designed for optimal coil delivery, deployment, and detachment into the aneurysm, addressing the procedural precision requirements of complex endovascular cases. Medtronic's presence in both the detachable coil market and the broader neurovascular space, including flow diverter platforms, positions the company across multiple treatment modalities as the competitive landscape evolves.
Terumo was the third-leading competitor in the detachable coil market in 2025. The company competes through its MicroPlex coil system and the Hydrocoil embolic system, offering coverage across both bare platinum and coated coil categories. Terumo's portfolio addresses a range of aneurysm sizes and treatment scenarios, and its position in the coated coil segment differentiates it within a market where bare platinum products continue to dominate by volume.
Technology and Practice Trends
Geography
This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
The Global Detachable Coil Market Report from iData Research answers these questions with procedure-aware models, company share analysis, and pricing detail. Use it to quantify demand, benchmark competitors, and plan commercial strategy across a market defined by near-flat growth and intensifying competitive dynamics.